20.01.2020 DEINOVE announces its financial calendar for 2020 DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
09.12.2019 DEINOVE and ESPCI Paris obtain funding from the ANR to develop the Deinodrop technology The Deinodrop technology will be co-developed by ESPCI and DEINOVE to accelerate the discovery and identification of bacteria producing new...
06.12.2019 Evolution in DEINOVE's governance Emmanuel PETIOT will resign as Chief Executive Officer ("CEO") as of December 31, 2019 Dr. Charles WOLER, Chairman of the Board of...
04.11.2019 New product preview at In-Cosmetics Asia 2019: a second innovative carotenoid from DEINOVE This new carotenoid has the particularity of absorbing blue light, which is responsible for premature skin ageing, the appearance of skin...
15.10.2019 DEINOVE selected for a presentation at BARDA Industry Day 2019 in Washington DC DEINOVE will present DNV3837/DNV3681, its antibiotic candidate targeting both urgent threats to public health and bioterrorism pathogens...
26.09.2019 2019 Half-year consolidated results: Deinove’s progress coming to fruition Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...
23.09.2019 Integration of CRISPR-cas9 technology to accelerate the discovery of innovative antibiotics DEINOVE strengthens its expertise in the genetic engineering of rare and varied microorganisms to accelerate the discovery and optimization...
18.09.2019 The efficacy of Hebelys® once again demonstrated and promoted in the International Journal of Cosmetic Science New in vitro and clinical efficacy data have been published; Sphingomonas hydrophobicum extract, the active substance of Hebelys®,...
09.07.2019 Issuance of notes convertible into new shares for a maximum amount of €15M. Issuance of a first €2.2 million tranche DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
24.06.2019 DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019 Major Steven Zumbrun (USAMRIID [1] , U.S. Department of Defense) presented data on the in vitro assessment of DNV3681 against pathogens...